VRTX

Vertex Pharmaceuticals
D

VRTX

450.27
USD
6.67
(1.50%)
مغلق
حجم التداول
56,054
الربح لكل سهم
18
العائد الربحي
-
P/E
-118
حجم السوق
115,628,069,390
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 10 أشهر
buy
2024-08-22 05:31
VRTX Chart
المزيد
أصول ذات صلة
ABBV
ABBV
1.750
(0.95%)
185.510 USD
AMGN
AMGN
4.92
(1.81%)
277.47 USD
BIIB
BIIB
1.503
(1.20%)
126.300 USD
BMRN
BMRN
0.600
(1.11%)
54.710 USD
GILD
GILD
1.035
(0.97%)
107.225 USD
INCY
INCY
1.770
(2.63%)
69.040 USD
LLY
LLY
8.32
(1.08%)
778.79 USD
REGN
REGN
10.87
(2.13%)
522.23 USD
المزيد
الأخبار المقالات

العنوان: Vertex Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.